🟠 Moderate Evidence
Vitamin B12 absorption is not a single pathway but a dual mechanism that shifts in importance depending on dose. The first and most efficient route uses intrinsic factor (IF), a protein produced by parietal cells in the stomach that binds B12 and transports it across the intestinal wall, while the second relies on passive diffusion—a low-efficiency but scalable backup that becomes dominant at high supplement doses. Understanding this distinction has practical implications for treating patients with pernicious anemia and for optimizing B12 supplementation strategies.
Key takeaways
- Intrinsic factor pathway absorbs B12 efficiently but saturates at approximately 1.5 µg per dose, making it dose-limited
- Passive diffusion absorbs only 1–2% of any oral dose but scales with dose size, becoming the primary route at supplement doses
- At 1,000 µg oral dose, total absorption reaches roughly 13 µg—over five times the daily requirement—of which ~10 µg comes from passive diffusion alone
- High-dose oral B12 may serve as an alternative to injections for intrinsic factor deficiency, though evidence remains limited in quality
Study at a Glance
| Source | Scandinavian Journal of Gastroenterology |
| Study type | Radioisotope tracer absorption study |
| Population | Healthy volunteers receiving radiolabeled cyanocobalamin |
| Key measurement | Whole-body retention of B12 across multiple dose levels |
| Publication year | 1971 |
B12 Absorption Efficiency Declines Sharply with Dose, but Total Amount Absorbed Rises
Percentage of oral dose retained versus actual B12 absorbed (µg), based on Adams et al. (1971) and NIH data
Source: Adams et al., Scandinavian Journal of Gastroenterology, 1971; NIH Office of Dietary Supplements | Georgian Medical Journal News
The intrinsic factor pathway: efficient but dose-limited
The primary B12 absorption mechanism involves intrinsic factor, a glycoprotein synthesized by gastric parietal cells in the stomach. According to the NIH Office of Dietary Supplements, IF binds to dietary B12 in the small intestine and facilitates its transport across the intestinal epithelium via a receptor protein called cubilin, located in the distal ileum. This is an active, saturable process—meaning it operates at maximum capacity once the IF-binding sites are filled.
The ceiling effect is critical: Adams and colleagues, in their 1971 study published in the Scandinavian Journal of Gastroenterology, used radiolabeled cyanocobalamin to measure whole-body retention across graded doses. At a 1 µg dose—roughly half the recommended dietary allowance (RDA)—approximately 50% was retained. This percentage dropped to 20% at 5 µg and just over 5% at 25 µg. The drop-off reflects IF saturation: once the intrinsic factor binding capacity is exceeded, no additional B12 can be transported via this route, regardless of how much more is consumed.
At 1 µg of oral B12, roughly 50% is retained via intrinsic factor. At 25 µg, retention falls to just 5%, demonstrating saturation of the IF pathway at approximately 1.5 µg per dose.
— Adams et al., Scandinavian Journal of Gastroenterology (1971)
Passive diffusion: the low-efficiency backup that scales with dose
The second absorption mechanism is passive diffusion across the intestinal lining, independent of intrinsic factor. The NIH reports that approximately 1 to 2% of any oral B12 dose diffuses passively across the entire length of the small intestine. At dietary doses—typically 1–5 µg—this contribution is negligible compared to IF-mediated transport. But as dose increases, the absolute amount absorbed via diffusion increases proportionally.
The NIH Office of Dietary Supplements reported absorption rates of approximately 2% at 500 µg and 1.3% at 1,000 µg. Although the percentage remains low, the actual amount absorbed is substantial: at 1,000 µg, approximately 13 µg enters circulation, of which roughly 10 µg derives from passive diffusion. This is why high-dose oral supplementation can deliver clinically meaningful amounts of B12 to systemically deficient patients.
This shift in absorption mechanism explains why B12 supplements at pharmacy strength (typically 500–1,000 µg per dose) are far more effective than food sources alone. Read more about clinical updates on nutrient absorption in the GMJ News clinical resource.
High-dose oral B12 as an alternative to injections: promise and caution
For patients with pernicious anemia—an autoimmune condition destroying gastric parietal cells and eliminating intrinsic factor production—injectable B12 has been the gold standard for decades. The NIH notes that high-dose oral supplementation “may be another treatment option” for intrinsic factor deficiency, though injections remain standard first-line therapy and the available randomized controlled trials comparing the two approaches are considered limited in quality.
The theoretical basis is sound: even at 1% efficiency, passive diffusion from a 1,000 µg dose delivers 10 µg—well above the 2.4 µg RDA and sufficient to correct systemic deficiency over time. However, this requires patient adherence and regular monitoring. The lack of robust, high-quality comparative trials means clinicians and patients must weigh oral convenience against the reliability of intramuscular injections on a case-by-case basis. For prescribing guidance on B12 formulations and dosing regimens, see our pharmacy and prescribing resources.
What this means
Frequently asked questions
Why does B12 absorption percentage drop so dramatically at higher doses?
The intrinsic factor pathway saturates—it has a maximum carrying capacity of roughly 1.5 µg per dose. Once all IF-binding sites are occupied, no more B12 can be transported via this route. Any additional B12 must rely on inefficient passive diffusion, which explains the sharp drop in absorption percentage. However, the total amount absorbed continues to rise because passive diffusion scales with dose.
If I take a 1,000 µg B12 supplement, how much actually gets absorbed?
Approximately 13 µg (1.3% of the dose) enters your bloodstream, of which roughly 10 µg comes from passive diffusion and a negligible amount from intrinsic factor (which is already saturated at lower doses). This 13 µg is more than five times your daily requirement, which is why high-dose oral supplements can correct deficiency over weeks to months.
Can high-dose oral B12 completely replace injections for pernicious anemia?
The NIH states that high-dose oral B12 “may be another treatment option” but acknowledges that available randomized controlled trials are limited in quality. Injections remain the standard first-line therapy. Oral supplementation may work if a patient is adherent and monitored regularly, but evidence for non-inferiority is not yet robust enough to recommend it universally.
As research advances and more rigorous trials comparing oral and parenteral B12 strategies emerge, clinical guidance may evolve. For now, the dual-pathway absorption mechanism explains why high-dose oral supplementation has merit in specific contexts—but also why standard injectable therapy remains the evidence-backed default for patients with absent or severely compromised intrinsic factor production.
Source: Adams et al., Scandinavian Journal of Gastroenterology, 1971; NIH Office of Dietary Supplements, Vitamin B12 Fact Sheet for Health Professionals
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
